Alpha-Lipoic Acid and Honokiol Composition for Neuropathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions for treating neuropathies, particularly those containing alpha-lipoic acid, often require high doses that increase side effects without providing better symptom relief, and there is a lack of effective combinations with honokiol for enhancing neurotrophic activities.
Innovation Solution
A composition combining alpha-lipoic acid with honokiol in specific weight ratios (1-30%) along with gamma-linolenic acid, selenium, and B group vitamins, formulated for oral administration, which enhances the efficacy of alpha-lipoic acid in treating neuropathic pain and promoting neurite extension and cell survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of alpha-lipoic acid are administered to improve treatment efficacy, then symptom relief is enhanced, but side effects increase
Solution Approach 1:
The patent combines alpha-lipoic acid with honokiol (a phenolic compound from Magnolia bark) to create a composite therapeutic formulation. This combination allows for synergistic effects where honokiol enhances the neurotrophic and antioxidant activities of alpha-lipoic acid, enabling effective treatment at lower doses and thereby reducing side effects while maintaining or improving therapeutic efficacy.
2Reliability
If higher doses of alpha-lipoic acid are used to improve symptom relief, then treatment response improves, but side effects such as nausea, vomiting and dizziness increase
Solution Approach 1:
The patent changes the dosing parameters by combining alpha-lipoic acid with honokiol, allowing for lower doses of alpha-lipoic acid to achieve the same therapeutic effect. This parameter change in dosage composition directly reduces gastrointestinal side effects while maintaining symptom relief efficacy.
3Device complexity
If single-ingredient compositions are used to simplify treatment, then formulation complexity is reduced, but treatment efficacy is limited
Solution Approach 1:
The patent creates a composite formulation combining alpha-lipoic acid and honokiol in specific ratios. This composite approach enhances neurotrophic activity and treatment efficacy compared to single-ingredient compositions, while maintaining a relatively simple two-component formulation that does not significantly increase complexity.
Data Source
AI summary
The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.